Kumthekar A, et al. - In this retrospective cohort study of Veterans, investigators estimated 121 candidates between January 1, 2010, and December 31, 2016, to evaluate the consequence of direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection on variations in pain intensity and prescription opioid use. They noticed an average reduction in pain scores with 0.6 points after treatment (average pre-treatment pain, 4.4). They found a decrease of 2.9 mg in morphine equivalent daily dose (MEDD) among 67 subjects who were given chronic opioid therapy at baseline with an average pre-treatment MEDD, 52.4 mg (SD = 62.5 mg) and post-DAA treatment average MEDD, 49.5 mg (SD = 69.3 mg). Twelve individuals entirely discontinued opioid use.